Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.
about
Cardiac toxicity of trastuzumab in elderly patients with breast cancerInfracentimetric HER-2 positive breast tumours-review of the literaturePromising oncolytic agents for metastatic breast cancer treatmentUnderstanding cardiovascular injury after treatment for cancer: an overview of current uses and future directions of cardiovascular magnetic resonanceCardiac effects of anticancer therapy in the elderlyCardiovascular Health of Patients With Cancer and Cancer Survivors: A Roadmap to the Next LevelThe effects of exercise on cardiovascular outcomes before, during, and after treatment for breast cancerAdjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care?Cardio-Oncology: A Focused Review of Anthracycline-, Human Epidermal Growth Factor Receptor 2 Inhibitor-, and Radiation-Induced Cardiotoxicity and ManagementCardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the MatterCardiac risk in the treatment of breast cancer: assessment and management.Sex differences in cardiovascular disease - Impact on care and outcomes.Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs) to Monitor Compound Effects on Cardiac Myocyte Signaling Pathways.Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies.Trastuzumab-induced cardiotoxicity in elderly women with HER-2-positive breast cancer: a meta-analysis of real-world data.Cardio-oncology: what you need to know now for clinical practice and echocardiography.Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.Long-term risk of medical conditions associated with breast cancer treatmentCardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors.Sympathetic nervous system alterations with HER2+ antagonism: an early marker of cardiac dysfunction with breast cancer treatment?Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclinesCardiovascular disease in adult survivors of childhood cancer.Risk of cardiovascular adverse events from trastuzumab (Herceptin(®)) in elderly persons with breast cancer: a population-based study.HER2 signaling pathway and trastuzumab cardiotoxicity.Cancer and cardiovascular disease: the use of novel echocardiography measures to predict subsequent cardiotoxicity in breast cancer treated with anthracyclines and trastuzumabCardiovascular toxicities from systemic breast cancer therapy.Safety and tolerability of docetaxel, cyclophosphamide, and trastuzumab compared to standard trastuzumab-based chemotherapy regimens for early-stage human epidermal growth factor receptor 2-positive breast cancerRisk of trastuzumab-related cardiotoxicity in early breast cancer patients: a prospective observational study.Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumabCardiac safety of the adjuvant Trastuzumab in a Moroccan population: observational monocentric study of about 100 patientsDevelopment and Validation of Endovascular Chemotherapy Filter Device for Removing High-Dose Doxorubicin: Preclinical StudyTrastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice.Histone deacetylase inhibitors improve the replication of oncolytic herpes simplex virus in breast cancer cellsThe labour market, psychosocial outcomes and health conditions in cancer survivors: protocol for a nationwide longitudinal survey 2 and 5 years after cancer diagnosis (the VICAN survey).Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations.Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers.Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer.Angiopoietin-2 blocking antibodies reduce early atherosclerotic plaque development in mice.Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis.
P2860
Q26741182-46DFECE0-461E-459C-ACBA-EB879FB19256Q26774597-202FB4CE-6E7A-4B34-AEA3-59FBB4733174Q26830620-23BA9CA9-F3B0-4133-8716-BBA2A9B72C81Q26859193-7FEB8315-DA4A-45A6-94DB-655D2C330612Q26863244-0FA7C020-4AAF-44C1-A6AD-12199121E21DQ26864094-F78396FA-2A53-40B4-AE64-DFD77BE037FEQ26999300-F386B5C0-2EC2-4940-8FD4-52FD4238D2D1Q27025860-052FFF1E-6F9F-4AB3-ACE8-027D85BA40E1Q28068290-C7B337F6-C71F-4497-85AE-3B8080C23CD5Q28075864-760CFAE2-F1C9-4BFD-BD1F-EF7B7BE41BF4Q28081385-B2FD4E80-AE85-4769-8BF6-28A70C334F0BQ30234726-93BC1E9D-031B-4EFB-9B90-603A689B4A2DQ30402943-29C01C4E-543F-4C47-87C4-E3E3AC181F41Q30426853-309B1F95-9D89-4B3F-AD8E-25DE9AB901CEQ31004660-56503A4A-3F47-46E6-B999-69C2F95E7297Q33701308-66C165B8-F946-4DD7-A1D8-C06CEAC379DCQ33824842-36A689D7-AD55-48E9-B05A-F14A6830195BQ33862786-4B6DDE99-E8F9-44E2-935D-CC12EEFB4571Q33895877-1A20CFEC-6FF4-4523-9089-6E85BE2549E2Q33949465-D9364474-1535-4E1D-BC7F-0E4B0E857808Q33988329-D302D62D-4156-49DB-A83F-B01C71722CE3Q34023749-23C2C231-299D-4AB8-8BA9-F2BEA12ACDF7Q34042984-B6801DD3-CC6D-4B6D-8832-AB9F7E2D4867Q34049037-8E05284A-F176-4152-B00C-76137207EB00Q34328064-9521CB4C-9EBA-40FC-9D7B-323C95611EA4Q34474264-BA3FF38C-A5B2-414E-B611-4573749DA31FQ34630349-E97FDEE1-5999-4F08-B295-8547D13EE9FAQ34779671-1ADE4D77-D9F0-4602-9C5E-C6C5AAFD63D6Q34779675-0D61A7EE-E472-4D04-B1DC-6B89E1435D90Q34855776-4BA70832-E100-4D6E-9A9E-0A5310B5A114Q34975825-A41E19B6-E4C9-4DEF-94F8-5DC31F207F17Q34981443-804B68CD-83C1-4973-BA4F-195C56FC2665Q35047415-02EDEB00-0E44-45EA-8D7A-D0D3C1DE1A8DQ35126723-E127E239-3232-4131-9B43-EC8537B131C3Q35277965-63848865-B7C8-4412-A28A-79F9640D0C08Q35490056-65D16E72-3962-46A3-8F59-5EDD35342EACQ35562745-A6A4D5C7-1BF5-41D4-B58E-ED09F186A6A0Q35880224-A94B7ABF-54D4-4B07-81B6-67E2353DE6A8Q35995921-9BF662B3-93A1-4E0D-96B3-29E3059C524BQ36085651-983CC7C3-D934-4C53-996F-3AB184355C90
P2860
Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Risk of heart failure in breas ...... a retrospective cohort study.
@ast
Risk of heart failure in breas ...... a retrospective cohort study.
@en
type
label
Risk of heart failure in breas ...... a retrospective cohort study.
@ast
Risk of heart failure in breas ...... a retrospective cohort study.
@en
prefLabel
Risk of heart failure in breas ...... a retrospective cohort study.
@ast
Risk of heart failure in breas ...... a retrospective cohort study.
@en
P2093
P2860
P50
P356
P1476
Risk of heart failure in breas ...... a retrospective cohort study.
@en
P2093
Adedayo A Onitilo
Andrew N Freedman
David J Magid
Edward H Wagner
Erin J Aiello Bowles
Katrina A B Goddard
Larissa Nekhlyudov
Larry A Allen
Laurel A Habel
Pharmacovigilance Study Team
P2860
P304
P356
10.1093/JNCI/DJS317
P407
P577
2012-09-01T00:00:00Z